VectivBio Highlights Presentation Of New Data Supporting Apraglutide For Treatment Of Short Bowel Syndrome at American Society Of Parenteral, Enteral Nutrition Conference
-- Apraglutide well-tolerated and does not require dose-adjustment in patients with severe renal disease --
-- Results demonstrate potential to reach 28% of SBS-IF patients with renal dysfunction who are underserved by